- Home
- BRO vs JAZZ Comparison
BRO vs JAZZ Comparison
Compare BRO & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRO | JAZZ |
|---|---|---|
| Founded | 1939 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.0B | 16.1B |
| IPO Year | 1994 | 2007 |
Fundamental Metrics
Financial Performance| Metric | BRO | JAZZ |
|---|---|---|
| Price | $69.05 | $209.70 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 21 | 22 |
| Target Price | $74.67 | ★ $294.64 |
| AVG Volume (30 Days) | ★ 2.3M | 772.2K |
| Earning Date | 10-26-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.97% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.90 | ★ 7.17 |
| Revenue | ★ $5,902,000,000.00 | $1,618,693,000.00 |
| Revenue This Year | $21.20 | $10.65 |
| Revenue Next Year | $4.30 | $5.76 |
| P/E Ratio | $35.66 | ★ $29.92 |
| Revenue Growth | ★ 22.83 | N/A |
| 52 Week Low | $53.81 | $128.80 |
| 52 Week High | $90.46 | $266.38 |
Technical Indicators
Market Signals| Indicator | BRO | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 65.70 | 27.05 |
| Support Level | $68.71 | $194.77 |
| Resistance Level | $70.12 | $241.39 |
| Average True Range (ATR) | 1.39 | 7.30 |
| MACD | 1.09 | -1.93 |
| Stochastic Oscillator | 95.44 | 4.39 |
Price Performance
Historical ComparisonAbout BRO Brown & Brown Inc.
Brown & Brown Inc is a diversified insurance agency, wholesale brokerage, insurance programs, and service. The company's business is divided into two reportable segments: (i) the Retail segment, and (ii) the Specialty Distribution segment. The Retail segment provides a broad range of insurance products and services to commercial, public and quasi-public entities, and to professional and individual customers, as well as non-insurance warranty services and products through automobile and recreational vehicle dealer services businesses. The Specialty Distribution segment consists of wholesale brokerage and specialty businesses. Its geographic area is U.S, U.K and Others.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.